This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (39)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Janet L. Wilterdink, MD; J. Donald Easton, MD

Arch Neurol. 1999;56:1087-1092.

Background  The second European Stroke Prevention Study (ESPS-2) recently reported a substantial benefit of dipyridamole combined with aspirin over aspirin alone in the prevention of stroke. This appears to be at odds with previous studies suggesting that dipyridamole adds nothing to aspirin alone.

Objectives  To review and compare the results of ESPS-2 and previous studies of dipyridamole plus aspirin and aggregate them in a meta-analysis.

Methods  We combined the detailed data provided by the Antiplatelet Trialists' Collaboration on the previous studies of dipyridamole plus aspirin with the results from ESPS-2. The data on the previous trials were listed in the appendix of the 1994 publication of the Antiplatelet Trialists' Collaboration.

Results  The results of our meta-analysis demonstrate that for the outcome of nonfatal stroke, ESPS-2 overwhelms previous data, which, even in the aggregate, did not include enough patients or outcome events to exclude efficacy for the combination of dipyridamole and aspirin. Differences between ESPS-2 and previous studies, which may have contributed to different results, include the doses and preparations of aspirin and dipyridamole.

Conclusions  The ESPS-2 showed that dipyridamole alone prevents stroke. More importantly, it showed a substantial benefit for dipyridamole combined with aspirin over aspirin alone. When the ESPS-2 data are aggregated with the 14 previous trials of dipyridamole combined with aspirin over aspirin alone, the combination reduces the risk of stroke by 23% over aspirin alone. Nevertheless, important questions remain unanswered. We conclude that another randomized clinical trial showing a significant benefit of the combination of dipyridamole plus aspirin over aspirin alone may be needed before the addition of dipyridamole to aspirin is widely accepted for prevention of stroke.

From the Department of Neurology, Rhode Island Hospital, and the Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(9):1169-1171.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of Aspirin Plus Extended-Release Dipyridamole in Preventing Recurrent Stroke in High-Risk Populations
Sacco et al.
Arch Neurol 2005;62:403-408.
ABSTRACT | FULL TEXT  

Is Treatment With Aspirin Combined With Dipyridamole Really More Cost-effective Than Aspirin Alone?
Heidebrink
Arch Intern Med 2001;161:1236-1236.
FULL TEXT  

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Albers et al.
Chest 2001;119:300S-320S.
FULL TEXT  

Regular review: Prevention of ischaemic stroke
Gubitz and Sandercock
BMJ 2000;321:1455-1459.
FULL TEXT  

Dipyridamole Plus Aspirin in Cerebrovascular Disease
Cohen et al.
Arch Neurol 2000;57:1086-1087.
FULL TEXT  

Supplement to the AHA Guidelines for the Management of Transient Ischemic Attacks • Response to Dr Hughes:
Hughes et al.
Stroke 2000;31 :983-991.
FULL TEXT  

A New Old Therapy for Stroke Prevention
JWatch Neurology 2000;2000:6-6.
FULL TEXT  

Review: aspirin reduces the risk for stroke in patients with previous transient ischaemic attack or stroke but does not have a dose-response effect
Hart
Evid. Based Med. 2000;5:9-9.
FULL TEXT